NeuroSense Finalizes 1-for-20 Reverse Split, Effective September 14
NRSN sits 57% above its 52-week low of $0.25.
Summary
NeuroSense Therapeutics announced a 1-for-20 reverse stock split effective September 14, 2026, reducing outstanding shares from 37.9M to 1.9M to address Nasdaq listing requirements.
Key Events · Corporate Governance and Compliance · NRSN
-
Reverse Split Finalized at 1-for-20
Every 20 ordinary shares will be consolidated into 1, reducing outstanding shares from 37,938,036 to 1,896,902.
-
Trading Begins September 14
Post-split shares will begin trading on Nasdaq Capital Market on Monday, September 14, 2026, under new CUSIP M74240207.
-
Nasdaq Compliance Effort
The reverse split is aimed at regaining compliance with Nasdaq's minimum bid price requirement, following prior delisting warnings.
-
Fractional Shares Rounded Up
No fractional shares will be issued; all fractional entitlements will be rounded up to the nearest whole share.
Analysis · NRSN · Life Sciences
The reverse split is now set at 1-for-20, with trading on the adjusted basis to begin Monday, September 14, 2026. This reduces outstanding shares from 37.9 million to approximately 1.9 million, a move aimed at regaining compliance with Nasdaq's minimum bid price requirement. Given prior warnings of delisting risk and dwindling ATM capacity, the action is part of a broader effort to stabilize the listing and preserve access to capital.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 30.2% of the 2009 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.11%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NRSN was trading at $0.39 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $15.1M. The 52-week trading range was $0.25 to $1.98. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.